Skip to content

PHARMIMPULSE

Active General partnershipfounded 2015active for 11 yearsRue de la Bachée 86, 1380 LasneKBO/BCE: BE 0634.979.024 subsidiary of PALATINE
PHARMIMPULSE
Follow ReportCompare

Overview

Lifetime

9 annual accounts with figures on one time axis
peak €842,528 (2024)
€171,172▼ 79.7%
lowest -€81,057 (2025)
-€81,057 
peak €3,750 (2016)
-€77,307▼ €81,057
€187,007▼ 50.9%
peak 14.2 FTE (2018)
-not published
Board1 name since 2015
1 directorPaul RANSART
Owners3 names in the annual accounts
6.66%envergure invest and 1 other
Documentsfilings and deeds
27-09-202658 days late
2025abbreviated format
Gross margin from €842,528 to €171,172Loss of €81,057Reappointment: Paul RANSART (manager) 28-01Equity from €3,750 to -€77,307Debts from €380,611 to €187,007Investments €9,997

Key points

from the 2025 annual accounts

Equity

-€77,307
201920202021202220242025

Debts exceed assets in financial year 2025.

Debts

€187,007 170% of the balance sheet
Financial debts 8%Suppliers 8%Taxes and wages 39%Other 46%

Investments

€9,997 6.8 × depreciation
20212025

Green is investment, beige is depreciation.

Staff

5.5 FTE from 14.2 in 2018

Between 2018 and 2025, 61% of the full-time equivalents disappeared.

Liquidity

0.50 was 0.99 in 2024

Short-term debts fell from €380,611 to €187,007.

Position in the sector

-70.5%

Lower solvency than 91% of companies in employment activities. Sector median 24.2% · 377 companies.

2025 accounts filed 58 days after the deadlineStaff (FTE) -56%: other schema

Checked score

51
Fair
Financially stronger than 5% of micro companies in employment activities (NACE 78)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
1.9% Moderate
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.3% across 1,379 companies (NACE 78, micro).

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 2.1% 01-2025: 2.9%▲ +0.8 percentage points vs 12-2024 02-2025: 2.9%● unchanged vs 01-2025 03-2025: 3.1%▲ +0.2 percentage points vs 02-2025highest value 04-2025: 2.8%▼ -0.3 percentage points vs 03-2025 05-2025: 2.8%● unchanged vs 04-2025 06-2025: 2.7%▼ -0.1 percentage points vs 05-2025 07-2025: 2.7%● unchanged vs 06-2025 08-2025: 2.7%● unchanged vs 07-2025 09-2025: 2.7%● unchanged vs 08-2025 10-2025: 2.7%● unchanged vs 09-2025 11-2025: 1.0%▼ -1.7 percentage points vs 10-2025 12-2025: 1.0%● unchanged vs 11-2025 01-2026: 1.0%● unchanged vs 12-2025 02-2026: 1.0%● unchanged vs 01-2026 03-2026: 0.9%▼ -0.1 percentage points vs 02-2026 04-2026: 1.0%▲ +0.1 percentage points vs 03-2026 05-2026: 1.0%● unchanged vs 04-2026 06-2026: 1.0%● unchanged vs 05-2026 07-2026: 0.9%▼ -0.1 percentage points vs 06-2026lowest value 08-2026: 1.0%▲ +0.1 percentage points vs 07-2026 09-2026: 1.2%▲ +0.2 percentage points vs 08-2026 10-2026: 1.9%▲ +0.7 percentage points vs 09-2026 11-2026: 1.9%● unchanged vs 10-2026

Financial strength
Weak

0equity -70.5% of total assets
4short-term debt 170.5% · cash 2.9%
0return on assets -73.9%

Score breakdown

raises risk
Loss of €81,057 (financial year 2025)
Last filed accounts filed 58 days late; 3 of the last 3 accounts late
lowers risk
Size: total assets €109,700
Legal form: general partnership
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 78, micro). It does better than 5% of them on solvency, 5% on liquidity, 8% on profitability and 1% on growth.

The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 6,907 companies had the same profile as PHARMIMPULSE has now. Each dot stands for 18 companies, two years later.

85.5%
were still trading
8.1%
stopped another way
5.8%
went bankrupt
  • Micro
  • 10 to 20 years old
  • negative equity
  • a loss of 10% of the balance sheet or more

Another 0.6% stopped without a precise date, possibly only after those two years.

That fits the bankruptcy probability of PHARMIMPULSE itself: 1.9% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,907 companies, not a prediction for PHARMIMPULSE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

No credit on open account

Liquidity is insufficient, with a current ratio of 0.5 (0.99 in 2024), below 1. Short-term debt is 170.5% and cash 2.9% of total assets. Equity is negative.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises risk
lowers risk · Size: total assets €109,700
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Loss of €81,057 (financial year 2025)
NBB · annual accounts
raises risk · Last filed accounts filed 58 days late; 3 of the last 3 accounts late
NBB · filings
lowers risk · Legal form: general partnership
KBO
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
18192021222425
2018 to 2025 · latest year -€77,307
raises risk · 2025 accounts filed 58 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-09-2026, 58 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 9 filings
Deviation from the deadline
2025
58 days late
2024
82 days late
2022
147 days late
2021
31 days late
2020
61 days late
2019
91 days late
2018
27 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 71 days after the deadline. In the sector (NACE 78), the median for financial year 2024 was 14 days before the deadline, and 30% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 30 September (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

PR
Paul RANSART
Manager, since 11-08-2015
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0634979024
Reappointment: Paul RANSART (manager) “Toutes activités de conseils en matière de marketing,merchandising,aménagement,communication,management et…” (deed in French) · Legal-form conversion: from economic interest grouping to general partnership · General meeting of 16-07-2024 · Gazette deed
Incorporation published on 20-08-2015 · Gazette deed
First establishment Rue de la Bachée 86, Lasne
All 13 events

Comparable companies

same main activity, similar in size and age
Company
PHARMIMPULSE Lasne - - -70.5% -
Solid'Emplois groupement d'employeurs Brussels €217,528 0.4% 43.2% -
HEMERA CONSULTING Wavre - - 12.7% -
Huyghe HR Services Oostkamp - - 80.7% -
Bruma Consulting Rotselaar - - 17.0% -
Your Oxygen Kontich €156,520 -44.4% -1207.3% 3.3
Afrik Interim Brussels - - -95.5% -

These companies have the same main activity as PHARMIMPULSE: temporary employment agencies and other provision of personnel (NACE 78200). They are comparable in size and age: total assets between €72,100 and €161,000, founded between 2012 and 2018.

Official details

Source: KBO
Status
Active since 11-08-2015Normal situation
Activity
Temporary employment agencies and other provision of personnelNACE 78200and 2 others
Establishment unit
2.245.120.8241380 Lasne, since 11-08-2015
Financial year end
31 December
Peppol
Reachable since 31-12-2025
Company details

Annual accounts 2025

€171,172▼ 79.7%
≈ €440,000estimated
€81,057
-€77,307
€109,700▼ 71.5%
Employeeson 31-12-2025
6▼ 57.1%
Filing
Filed on 27-09-2026
Financials

Companies linked to PHARMIMPULSE

Insights on PHARMIMPULSE

PHARMIMPULSE files the abbreviated format. That format states no turnover. The gross margin fell from €395,048 in 2016 to €171,172 in 2025.

PALATINE holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 27-09-2026, 58 days late
€171,172
▼ 79.7%
-€71,463
▼ €74,879
-€81,057
-€94,292
▼ €89,590
-70.5%
▼ 71.4 percentage points
0.50
▼ 0.49

The turnover shown is an estimate from the gross margin.

Turnover ≈ €440,000. Estimated: probably between €270,000 and €820,000.

Balance sheet

balance sheet total €109,700 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

-70.5%

Higher than 8% of 377 companies in 2025.

0.50

Higher than 9% of 367 companies in 2025.

-73.9%

Lower than 95% of 371 companies in 2025.

PHARMIMPULSE Middle half of the sector 80% of the sector Abbreviated accounts in employment activities (NACE 78)

Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: bottom quarter · Staff: middle half

Staff

€43,776

Staff costs divided by the average number of full-time equivalents.

-8 people

people who joined people who left

In 2025, 2 people joined and 10 left.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242022202120202019201820172016
Balance sheet: assets
20/58 109,700384,361219,964148,612172,674174,936162,852160,682201,121
21/28 16,9858,45311,00212,276-----
21 9,398--------
22/27 7,5878,45311,00212,276-----
24 408--------
26 7,1788,45311,00212,276-----
29/58 92,715375,908208,962136,335172,674174,936162,852160,682201,121
40/41 88,720360,040184,610113,499160,884159,379159,167119,537195,745
40 52,634306,286182,360111,249142,069157,129156,917117,287193,494
41 36,08653,7542,2502,25018,8152,2502,2502,2502,250
54/58 3,17515,05024,35222,83711,79015,5573,68441,1445,376
490/1 820818-------
Balance sheet: equity and liabilities
10/49 109,700384,361219,964148,612172,674174,936162,852160,682201,121
10/15 -77,3073,7503,7503,7503,7503,7503,7503,7503,750
10/11 3,7503,7503,7503,7503,7503,7503,7503,7503,750
100 -----3,7503,7503,7503,750
11 3,7503,750-------
1109/19 3,7503,750-------
14 -81,057--------
17/49 187,007380,611216,214144,862168,924171,186159,102156,932197,371
42/48 187,007380,611216,214143,062168,924171,186154,302155,732192,571
43 14,10422,819-------
430/8 14,10422,819-------
44 14,775153,83733,71431,34210,0818,83011,44113,564112,461
440/4 14,775153,83733,71431,34210,0818,83011,44113,564112,461
45 72,776117,153163,14391,175158,843132,921142,860142,16860,110
450/3 30,71438,29264,87729,11752,65939,37727,14033,94433,395
454/9 42,06278,86198,26662,058106,18493,544115,720108,22426,716
47/48 85,35286,80319,35720,545-29,435--20,000
492/3 ---1,800--4,8001,2004,800
Income statement
76A ---3,328-----
9900 171,172842,528715,651522,423659,211595,002718,392628,341395,048
62 240,771837,838712,975521,475659,157594,643718,404628,313393,559
630 1,4641,2751,275469-----
640/8 400-------200
9901 -71,4633,4161,40147954359-11281,289
75/76B 1,136468-1-232--
75 1,136468-1-232--
65/66B 2,8073,8841,4014805436021281,289
65 2,8073,8841,4014805436021281,289
9903 -73,133--------
67/77 7,924--------
9904 -81,057--------
9905 -81,057--------
Appropriation of the result
9906 -81,057--------
Social balance sheet
9087 5.512.613.511.213.213.614.213.38.8
Hours worked1013 6,30523,22522,48819,80220,84021,61324,69822,10515,344
Document PDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 16 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 27-09-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2025 annual accounts filed 58 days after the deadline. Filed on 27 September 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00532092.

Financial year Type Filed Reference Document
31-12-2025 abbreviated format 27-09-2026 2026-00532092 PDF
31-12-2024 micro format 21-10-2025 2025-00547464 PDF
31-12-2022 micro format 25-12-2023 2023-00538485 PDF
31-12-2021 full format 31-08-2022 2022-20404961 PDF
31-12-2020 full format 30-09-2021 2021-70100014 PDF
31-12-2019 full format 30-10-2020 2020-66100485 PDF
31-12-2018 full format 27-08-2019 2019-52800188 PDF
31-12-2017 full format 30-08-2018 2018-54500548 PDF
31-12-2016 full format 25-08-2017 2017-47700348 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242022202120202019201820172016
-69,9994,6912,676948-----
-79,593--------
9,997-012,745-----
-11,875-1,51511,047-3,76811,873-37,46035,768-
-94,292-4,703-7,252-6,7263,7503,7508,5504,9508,550
-70.5%1.0%1.7%2.5%2.2%2.1%2.3%2.3%1.9%
0.500.990.970.951.021.021.061.031.04
--57.6638.6345.0545.6542.4341.8552.63
-73.9%--------
-24.941.211.911.97-----

EBIT margin: not included in this filing.

Debt to equity is not shown because equity is negative. Debt divided by negative equity means nothing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202231-12-2021
Employees at the balance-sheet date6141612
full-time513109
part-time1163
in full-time equivalents5.713.914.711.2
5.5-13.511.2
On a permanent contract6141310
Joined2-912
Left10-514

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item2025202420222021
Tangible fixed assets€512--€12,745
Intangible fixed assets€9,485---
Financial fixed assets€0---
€1,464€1,275€1,275€469

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on PHARMIMPULSE

The operating result for 2025 is a loss of €71,463, after a profit of €3,416 in 2024. It is the lowest result since 2016.

Equity is negative. Debt (€187,007) exceeds the balance-sheet total (€109,700).

Large changes and their cause
  • 2025 Staff (FTE) -56% on 2024. The accounts now follow the abbreviated format, last year the micro format.

Board & ownership

Board

1 director, last change in 2021
Paul RANSART
Manager
since 11-08-2015 6-year term from 2021
listed in the 2025 annual accounts, filed on 27-09-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“Article 28. - Représentation Le(s) gérant(s) de la société représente(nt) celle-ci à l'égard des tiers en justice.”
deed of 28-01-2025

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today
Paul RANSART
Manager
BoardRest of the term
Mandates as a list
  • Paul RANSART
    • Manager, from 11-08-2015 to date

See the board, name and registered office on a given date →

Control

Parent
PALATINE
Equity €487,128
Loss €60,905 in 2025 (loss €90,665 in 2024)
Checked score 51
100%
This company
PHARMIMPULSE
Equity -€77,307
Loss €81,057 in 2025

Further up the chainBLUESTONE 51.44%

and 2 other shareholders

Capital

Contribution
€3,750
Source
2025 annual accounts

Owners through the years

as the annual accounts name them
envergure invest
6.66%
6.66%
PHARMACIE DEFRE
6%6.66%
6.66%
PALATINE
100%
100% until 2024
Owners as a list

Source: lists of holdings in the owners' accounts

Articles of association

deed of 28-01-2025 (in French)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
“Totalité ou partie des parts sociales, non-dissolution,parts associé décédé reviennent héritiers légataires avec consentement tous associés”
Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
“Associés à majorité, liquidateurs peuvent exiger paiement associés prorata parts sociales”

Shareholders

3 owners

Owners 3

Network & group

Group

PALATINE has 4 direct subsidiaries (2024 accounts), the bar shows equity in euros
ParentPALATINE4 holdings, 1 country 2024 accounts

Belgium 4 Equity Result

  • BE PHARMIMPULSE -€77,307 result -€81,057
  • BE GHISPHARMA €349,657 result €14,291
  • BE EUROPHAR €230,230 result €242,204
  • BE PHARMARIVE €114,888 result -€19,028

Source: list of holdings in the 2024 accounts of PALATINE. Every holding stands with its own latest accounts.

Part of the group BLUESTONE Group, risk and exposure

Connections & network

1 current director
Depth

The network starts from the directors of PHARMIMPULSE. Every other company they run is a node.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

13 events since 2015

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBabbreviated format · 58 days late
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0634979024
Annual accounts 2024 filed PDFmicro format · 82 days late
Reappointment: Paul RANSART (manager)“Toutes activités de conseils en matière de marketing,merchandising,aménagement,communication,management et…” (deed in French) · Legal-form conversion: from economic interest grouping to general partnership · General meeting of 16-07-20244 points ▸
  • General meeting, 11-07-2024
  • Legal-form conversion, from economic interest grouping to general partnership
  • Director reappointment, Paul RANSART (manager)
  • General meeting, 16-07-2024
  • The deed holds 2 more points.

Open the deed in the Belgian Official Gazette

2023
Annual accounts 2022 filed PDFmicro format · 147 days late
2022
Annual accounts 2021 filed PDFfull format · 31 days late
2021
Annual accounts 2020 filed PDFfull format · 61 days late
2020
Annual accounts 2019 filed PDFfull format · 91 days late
2019
Annual accounts 2018 filed PDFfull format · 27 days late
2018
Annual accounts 2017 filed PDFfull format · 30 days late
2017
Annual accounts 2016 filed PDFfull format · 25 days late
2015
Incorporation PDFpublished on 20-08-2015
First establishment Rue de la Bachée 86, Lasne

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 11 August 2015, PHARMIMPULSE was incorporated.1 Total assets went from €162,852 in 2018 to €109,700 in 2025 and headcount from 14.2 to 5.5 full-time equivalents.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2018 and 2025

Company details

Identity

Enterprise number
0634.979.024
VAT number
BE 0634.979.024
Peppol ID
0208:0634979024
Other Peppol ID
9925:BE0634979024
Legal form
General partnership
Status
Active, normal situation
Founded
11-08-2015
Financial year
ends on 31 December
Peppol
Reachable since 31-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
PHARMIMPULSE in French
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 28-01-2025 (in French)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Rue de la Bachée 86, 1380 Lasne”
deed of 28-01-2025 (in French)

Activities

NACEBEL 2025
VAT activities
78200 Temporary employment agencies and other provision of personnel main activity
82100 Office administrative and support services
82990 Other business support services
Social security (RSZ) activities
82100 Office administrative and support services main activity
Codes under NACEBEL 2008
78300 Employment activities main activity
82110 Office administrative, office support and other business support activities
82990 Other business support services
PurposeThe purpose describes the activities the company may carry out under its articles.
“Toutes activités de conseils en matière de marketing,merchandising,aménagement,communication,management et gestion des points de vente et…”
16 activities
  1. Toutes activités de conseils en matière de marketing,merchandising,aménagement,communication,management et gestion des points de vente et particulièrement ceux liés au domaine de la santé et du bien-être tels que officines pharmaceutiques,parapharmacie,herboristerie,centre d'esthétique,spa;cette énonciation étant exemplative et non limitative;
  2. L'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des pharmaciens,et l'exploitation de laboratoires de recherches et d'analyse,de grossiste ou laboratoire pharmaceutique;
  3. L'achat,la vente,l'importation,l'exportation,la fabrication,l'industrialisation,la représentation,la distribution en gros et au détail,la commercialisation et le commerce sous toutes ses formes de tous produits et services chimiques,pharmaceutiques,allopathiques ou homéopathiques,diététiques,phytopharmaceutiques et vétérinaires,sous toutes leurs formes,notamment par le développement d'un savoir-faire destiné à assurer l'exploitation optimale d'officines pharmaceutiques,de tous articles de droguerie,de parfumerie,de cosmétique,d'hygiène,d'herboristerie,d'entretien,de nettoyage et de désinfection,de tous appareils,instruments et accessoires de chirurgie,d'acoustique,d'optique et d'orthopédie,bandagisterie,système d'alarme et autres produits s'y rapportant d'une quelconque façon ou pouvant y être adjoint utilement,et,d'une manière générale de tous appareils accessoires,instruments produits ou procédés se rattachant directement ou indirectement à l'exploitation d'une officine pharmaceutique,d'une parapharmacie,d'une herboristerie,d'un centre de bien-être,d'un centre d'esthétique,d'un spa,ou d'un laboratoire de recherche et d'analyses ainsi que la formation et les conseils en ces matières;
  4. L'achat et la vente de matériels,de matériaux,de mobiliers et d'aménagements liés aux activités décrites ci-avant;
  5. L'achat,la vente,l'échange,l'approbation,la concession,la constitution,le démembrement concernant tous biens ou droits réels immobiliers et toutes affaires relatives à ces biens,en ce compris l'exploitation,la gestion et la location de ces biens;
  6. La construction,la reconstruction,la transformation,la rénovation l'aménagement,la démolition,ainsi que toute entreprise relativement aux biens immobiliers bâtis ou non bâtis;
  7. Les expertises,études,les conseils,prêts et financements et opérations immobilières et de promotion;
  8. L'étude et la promotion immobilière et financière;
  9. La gestion de toutes sociétés commerciales belges ou étrangères;
  10. La prise de participations,majoritaires ou non,dans d'autres sociétés;
  11. La prise de participations dans toute entreprise,sous quelque forme que ce soit,l'exercice du contrôle,de la gestion,de l'administration,de la consultance favorisant la poursuite de l'objet de ces sociétés,notamment et dans la mesure de ces compétences par l'exercice de mandats sociaux ou non;
  12. La constitution,l'acquisition,la cession,la concession,la licence de droits de propriété industrielle,et de tous droits apparentés;
  13. L'importation et l'exportation de tous biens et services,le courtage international commercial,industriel,financier,mobilier et immobilier,et toute autre opération analogue par le mécanisme ou par les effets,ainsi que l'exercice à l'étranger,s'il y a lieu,de toutes les activités ci-dessus énumérées;
  14. La gestion de bâtiments et équipements(facilities management),les services de gestion d'immeubles au sens large,y compris tous services de nettoyage,tant intérieur qu'extérieur,l'élaboration et l'entretien de parcs,jardins,tennis et piscines,sécurité,déménagement des lieux et autres services se rapportant à l'exploitation d'un immeuble tant pour compte propre que pour celui de tiers;
  15. La gestion et l'entretien de bois,de parcs,de jardins et de terres,d'étangs,de tennis,de piscines;
  16. L'achat,la vente,la location,l'importation,l'exportation de tous types de véhicules.
deed of 28-01-2025 (in French)

Registered office and establishments

1 establishment
Establishment Since Unit number
Rue de la Bachée 86 registered office 1380 Lasne 11-08-2015 2.245.120.824

Location

registered office establishment approximate The establishment unit on the map

We would like to set cookies. That happens only with your consent. What we measure